1.1 Genomic Sequencing


A new approach to next-generation sequencing

We give doctors access to a variety of sequencing capabilities, all with full transcriptome and tumor/normal match. We partner with physicians and hospitals to augment a hospital's current offering by providing access to next-generation sequencing with cutting-edge analytics and an interactive machine learning platform that also leverages data across our platform.


Capable of analyzing and reporting on individual genes with clinical significance for specific cancer subtypes.

Capable of analyzing and reporting on individual genes with clinical significance for specific cancer subtypes.


Whole Exome

~ 20,000 Genes

Entire coding exome is sequenced; providing the broadest genomic coverage for analysis

Download Validation Summary

DNA sequencing using tumor/normal match

Utilizing our proprietary assays, we perform a tumor/normal matched analysis by sequencing both a tumor DNA sample and a normal DNA sample from blood or saliva to ensure that your report accurately distinguishes between your patient’s somatic and germline variants.

RNA sequencing

Utilizing our proprietary RNA extraction protocols, we perform high-quality RNA sequencing on all samples we sequence, where specimen quality and quantity allow. Profiling of whole RNA transcriptome provides molecular information that is complementary to DNA sequencing and can be clinically important. This allows for clinically validated unbiased translocation detection.


We believe the path to precision medicine is understanding patients’ clinical and molecular journey over time. For this reason, the xT test includes a second xT assay result* within 18 months of the initial result when a treating physician believes the patient would benefit from clinical care based on their current tumor biology. It is our hope that clinicians, researchers and most importantly, patients, will benefit from the novel discoveries that result from this longitudinal information. *All U.S.-based clinical patients who receive an xT test are eligible for a second xT assay result at no additional charge within 18 months of the initial result at the request of their physician. A new tumor sample and progress note are required for the second assay.


Bringing data and technology into clinical care

We've built a state-of-the-art, CAP-accredited and CLIA-certified lab. Our highly robotic laboratory is optimized for high-throughput clinical next-generation sequencing with a current capacity of over 100,000 patients annually. Sequencing is completed within two to three weeks of receiving patient samples.

Download our equipment overview


How to order the Tempus sequencing test

All Tempus tests must be ordered by a physician, and Tempus works directly with oncologists and pathologists to obtain normal and tumor samples. The provided kits include everything needed for specimen collection, including easy-to-follow instructions, specimen guidelines, and packaging for convenient and fast shipping to our lab.

Contact us to order a test
  1. Retrieve a Tempus blood or saliva collection kit. All required forms are contained in the box.
  2. Complete the requisition form contained within the kit. Physician and patient signatures are both required. Gather accompanying documents as noted on the form.
  3. Fax or email the requisition form and accompanying documents to Tempus. Once the requisition is received, we will request the tumor specimen from pathology.
  4. Retrieve a normal sample of blood or saliva from the patient, if required.
  5. Ship the normal sample using the enclosed clinical shipping package. Include all supporting documents in the package.


The Tempus Report

In about two weeks physicians receive a comprehensive report for each patient that highlights key findings, including actionable treatments, microsatellite instability (MSI) status, and tumor mutational burden (TMB) that can be immediately translated into cancer patient care.

Learn more about our clinical decision support tools